A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects With Active Proliferative Lupus Nephritis
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Anifrolumab (Primary)
- Indications Lupus nephritis
- Focus Therapeutic Use
- Acronyms TULIP-LN1
- Sponsors AstraZeneca
- 22 Aug 2016 Planned End Date changed from 1 Sep 2018 to 1 Sep 2019.
- 22 Aug 2016 Planned primary completion date changed from 1 Sep 2018 to 1 Sep 2019.
- 04 Feb 2016 According to an AstraZeneca media release, regulatory submissions in US, EU and Japan are anticipated in 2019.